Bifidobacterium longum: Gut-Brain, IBS, and Constipation Evidence (2026)
Updated April 2026 · Key strains: R0175, NCC3001 · Sources: Cochrane, PubMed, ISAPP
What It Is
Bifidobacterium longum is one of the most abundant bacterial species in the human colon and one of the first to colonise the infant gut after birth. It is a Gram-positive, anaerobic bacterium and a primary producer of short-chain fatty acids (especially acetate) from prebiotic fibre fermentation.
Unlike many Lactobacillus species, B. longum is a genuine long-term resident of the adult gut microbiome. Its abundance typically decreases with age, with the most dramatic decline occurring after infancy. Restoring B. longum populations through supplementation or dietary changes is an active area of microbiome research.
Two strains are most clinically studied. B. longum NCC3001 (Nestle Culture Collection) is notable for a 2017 RCT by Pinto-Sanchez et al. showing a significant reduction in depression and anxiety scores in IBS patients - the first clean psychobiotic evidence in a human RCT. B. longum R0175 (Lallemand/Rosell Institute) has evidence for reducing stress-related GI complaints in healthy adults.
What the Evidence Says
Gut-Brain Axis / Psychobiotic Effect
Emerging EvidenceThe NCC3001 strain's most discussed finding: Pinto-Sanchez et al. (Gastroenterology 2017) randomised 44 IBS-D patients to NCC3001 or placebo for 6 weeks. The probiotic group showed significant reductions in depression scores (HAD-D: P=0.044) and quality-of-life improvements but no significant change in gut symptom severity. Brain imaging (fMRI) showed reduced reactivity in the amygdala and fronto-limbic network. This is the "psychobiotic" finding. Important caveats: small sample, single RCT, IBS-specific population, not replicated independently at scale.
Cite: Pinto-Sanchez et al., Gastroenterology 2017; DOI:10.1053/j.gastro.2017.05.003
IBS Symptoms (General)
Emerging EvidenceB. longum is included in several multi-strain IBS probiotic trials with positive outcomes, but strain-specific effects are difficult to isolate from multi-strain formulations. The 2024 IBS network meta-analysis (PMC10490209) assigns B. longum-containing combinations emerging-tier evidence. B. infantis 35624 and L. plantarum 299v have stronger IBS-specific single-strain evidence.
Cite: Ford et al., Am J Gastroenterol 2024; PMC10490209
Constipation
Emerging EvidenceB. longum BB536 (Morinaga strain) has three Japanese RCTs showing improved stool frequency and consistency in constipation-prone adults. Effect was most pronounced in elderly populations. B. lactis BB-12 has stronger evidence for constipation; B. longum is a second-tier choice in this category. Combining with psyllium (prebiotic) may enhance the effect.
Cite: Nishida et al., Biosci Biotechnol Biochem 2004; Ogawa et al., J Nutr Sci Vitaminol 2019
Stress-Related GI Complaints in Healthy Adults
Emerging EvidenceR0175 strain (Lallemand) in combination with L. helveticus R0052 (sold as Probio'Stick and Biocultis) reduced self-reported psychological distress scores and GI distress in a 30-day RCT (Messaoudi et al., Br J Nutr 2011). Evidence is limited to a single industry-funded trial. Interesting mechanism but not replication-established.
Cite: Messaoudi et al., Br J Nutr 2011; industry-funded, limited independent replication
Dosing and Form
Clinical trials typically use 1-10 billion CFU of B. longum strains. The NCC3001 psychobiotic trial used 1 billion CFU/day, a notably lower dose than most probiotic trials. The BB536 constipation trials used 2-5 billion CFU/day. Most multi-strain supplements include B. longum as one component; check whether the specific strain designation matches the trial evidence you're interested in.
B. longum is an obligate anaerobe and sensitive to oxygen. Quality supplements should be produced and packaged under nitrogen-flush conditions. Refrigeration is recommended. Enteric-coated capsules improve viability through gastric acid.
Safety
B. longum has QPS (qualified presumption of safety) status in Europe and is used in infant formulas globally. No significant adverse events have been attributed to B. longum in clinical trials. Standard cautions apply: immunocompromised patients and those with CVCs should discuss probiotic use with a clinician. Transient gas and bloating in the first week of supplementation is possible.
Products Containing B. longum
Affiliate disclosure: links below may be affiliate links.
Seed DS-01 Daily Synbiotic
Emerging EvidenceContains multiple Bifidobacterium species including B. longum strains in the outer capsule prebiotic layer combination.
Garden of Life Mood+ Probiotics
Emerging EvidenceContains B. longum R0175 (the Lallemand psychobiotic strain) alongside other Lactobacillus strains. Targets the gut-brain axis.
Align Plus Complete Digestive Supplement
Emerging EvidenceContains B. longum and other strains alongside the flagship B. infantis 35624.